161 related articles for article (PubMed ID: 33046820)
1. Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand.
Yu J; Yang K; Zheng J; Zhao W; Sun X
Cancer Gene Ther; 2021 Jun; 28(6):590-601. PubMed ID: 33046820
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
3. Antitumor Activity of Nitazoxanide against Colon Cancers: Molecular Docking and Experimental Studies Based on Wnt/β-Catenin Signaling Inhibition.
Abd El-Fadeal NM; Nafie MS; K El-Kherbetawy M; El-Mistekawy A; Mohammad HMF; Elbahaie AM; Hashish AA; Alomar SY; Aloyouni SY; El-Dosoky M; Morsy KM; Zaitone SA
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069111
[TBL] [Abstract][Full Text] [Related]
4. Farnesoid X receptor (FXR) agonists induce hepatocellular apoptosis and impair hepatic functions via FXR/SHP pathway.
Zhang T; Feng S; Li J; Wu Z; Deng Q; Yang W; Li J; Pan G
Arch Toxicol; 2022 Jun; 96(6):1829-1843. PubMed ID: 35267068
[TBL] [Abstract][Full Text] [Related]
5. Farnesoid X receptor antagonizes Wnt/β-catenin signaling in colorectal tumorigenesis.
Yu J; Li S; Guo J; Xu Z; Zheng J; Sun X
Cell Death Dis; 2020 Aug; 11(8):640. PubMed ID: 32807788
[TBL] [Abstract][Full Text] [Related]
6. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
Di Matteo S; Nevi L; Costantini D; Overi D; Carpino G; Safarikia S; Giulitti F; Napoletano C; Manzi E; De Rose AM; Melandro F; Bragazzi M; Berloco PB; Giuliante F; Grazi G; Giorgi A; Cardinale V; Adorini L; Gaudio E; Alvaro D
PLoS One; 2019; 14(1):e0210077. PubMed ID: 30677052
[TBL] [Abstract][Full Text] [Related]
7. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
[TBL] [Abstract][Full Text] [Related]
8. The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway.
Attia YM; Tawfiq RA; Ali AA; Elmazar MM
Sci Rep; 2017 Oct; 7(1):12502. PubMed ID: 28970500
[TBL] [Abstract][Full Text] [Related]
9. Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression.
Yu J; Yang K; Zheng J; Zhao P; Xia J; Sun X; Zhao W
Cell Death Dis; 2022 Apr; 13(4):388. PubMed ID: 35449124
[TBL] [Abstract][Full Text] [Related]
10. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
[TBL] [Abstract][Full Text] [Related]
11. Disruption of TFGβ-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand.
Carino A; Biagioli M; Marchianò S; Scarpelli P; Zampella A; Limongelli V; Fiorucci S
Pharmacol Res; 2018 May; 131():17-31. PubMed ID: 29530598
[TBL] [Abstract][Full Text] [Related]
12. Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Bordoni M; Roselli R; Di Giorgio C; Baldoni M; Ricci P; Monti MC; Morretta E; Zampella A; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Sep; 1865(9):158733. PubMed ID: 32371093
[TBL] [Abstract][Full Text] [Related]
13. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.
Zhou J; Cui S; He Q; Guo Y; Pan X; Zhang P; Huang N; Ge C; Wang G; Gonzalez FJ; Wang H; Hao H
Nat Commun; 2020 Jan; 11(1):240. PubMed ID: 31932588
[TBL] [Abstract][Full Text] [Related]
14. Farnesoid X Receptor Activation Enhances Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells.
Kainuma M; Takada I; Makishima M; Sano K
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29958417
[TBL] [Abstract][Full Text] [Related]
15. Farnesoid X receptor activation induces antitumour activity in colorectal cancer by suppressing JAK2/STAT3 signalling via transactivation of SOCS3 gene.
Li S; Xu Z; Guo J; Zheng J; Sun X; Yu J
J Cell Mol Med; 2020 Dec; 24(24):14549-14560. PubMed ID: 33164339
[TBL] [Abstract][Full Text] [Related]
16. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
[TBL] [Abstract][Full Text] [Related]
17. Regulation of Intestinal UDP-Glucuronosyltransferase 1A1 by the Farnesoid X Receptor Agonist Obeticholic Acid Is Controlled by Constitutive Androstane Receptor through Intestinal Maturation.
Weber AA; Mennillo E; Yang X; van der Schoor LWE; Jonker JW; Chen S; Tukey RH
Drug Metab Dispos; 2021 Jan; 49(1):12-19. PubMed ID: 33154041
[TBL] [Abstract][Full Text] [Related]
18. Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms.
Guo C; LaCerte C; Edwards JE; Brouwer KR; Brouwer KLR
J Pharmacol Exp Ther; 2018 May; 365(2):413-421. PubMed ID: 29487110
[TBL] [Abstract][Full Text] [Related]
19. Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress.
Gai Z; Krajnc E; Samodelov SL; Visentin M; Kullak-Ublick GA
Mol Pharmacol; 2020 May; 97(5):314-323. PubMed ID: 32098797
[TBL] [Abstract][Full Text] [Related]
20. Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR.
Dong B; Singh AB; Guo GL; Young M; Liu J
Int J Mol Med; 2019 May; 43(5):1927-1938. PubMed ID: 30896855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
